Literature DB >> 11222397

Defective antifungal T-helper 1 (TH1) immunity in a murine model of allogeneic T-cell-depleted bone marrow transplantation and its restoration by treatment with TH2 cytokine antagonists.

A Mencacci1, K Perruccio, A Bacci, E Cenci, R Benedetti, M F Martelli, F Bistoni, R Coffman, A Velardi, L Romani.   

Abstract

Patients undergoing full haplotype-mismatched hematopoietic transplantations may experience severe intractable invasive fungal infections. To verify whether an imbalanced production of T-helper 1 (TH1) and TH2 cytokines may be responsible for susceptibility to fungal infections, C3H/HeJ (H-2(k)) recipient mice were lethally irradiated, received transplantations with T-cell-depleted allogeneic bone marrow (BM) cells from mice of H-2(d) haplotype, and were infected with Candida albicans. At different time-points after transplantation, mice were assessed for pattern of TH cytokine production and susceptibility to infection. The results show that a long-term, donor-type chimerism was achieved as early as 2 weeks after BM transplantation (BMT), at the time when high-level production of TH2 cytokines (interleukin-4 [IL-4] and IL-10) and impaired production of TH1 cytokines (interferon-gamma [IFN-gamma] and IL-12] were observed. At this time, mice were highly susceptible to both disseminated and mucosal infections, as indicated by decreased survival, uncontrolled fungal growth, and failure to develop protective TH1 immunity. However, a predominant production of TH1 cytokines was observed by week 5 after BMT, at the time when mice developed donor-type protective TH1 responses and were resistant to infections. Therapeutic ablation of IL-4 or IL-10 greatly increased resistance to candidiasis. These results indicate that a dysregulated production of TH cytokines occurs in mice undergoing T-cell-depleted allogeneic BMT. The transient predominant production of TH2 cytokines over that of IL-12 impaired the ability of mice to develop antifungal TH1 resistance, an activity that could be efficiently restored upon treatment with TH2 cytokine antagonists.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11222397     DOI: 10.1182/blood.v97.5.1483

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  15 in total

1.  Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice.

Authors:  J Brieland; D Essig; C Jackson; D Frank; D Loebenberg; F Menzel; B Arnold; B DiDomenico; R Hare
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

Review 2.  Immune defence against Candida fungal infections.

Authors:  Mihai G Netea; Leo A B Joosten; Jos W M van der Meer; Bart-Jan Kullberg; Frank L van de Veerdonk
Journal:  Nat Rev Immunol       Date:  2015-09-21       Impact factor: 53.106

Review 3.  Respiratory dendritic cells: mediators of tolerance and immunity.

Authors:  Ryan A Langlois; Kevin L Legge
Journal:  Immunol Res       Date:  2007       Impact factor: 2.829

4.  IL-33 and M2a alveolar macrophages promote lung defense against the atypical fungal pathogen Pneumocystis murina.

Authors:  Michael P Nelson; Benjamin S Christmann; Jessica L Werner; Allison E Metz; Jennifer L Trevor; Clifford A Lowell; Chad Steele
Journal:  J Immunol       Date:  2011-01-10       Impact factor: 5.422

5.  Protection of killer antiidiotypic antibodies against early invasive aspergillosis in a murine model of allogeneic T-cell-depleted bone marrow transplantation.

Authors:  Elio Cenci; Antonella Mencacci; Antonio Spreca; Claudia Montagnoli; Angela Bacci; Katia Perruccio; Andrea Velardi; Walter Magliani; Stefania Conti; Luciano Polonelli; Luigina Romani
Journal:  Infect Immun       Date:  2002-05       Impact factor: 3.441

Review 6.  The role of the IL-12 cytokine family in directing T-cell responses in oral candidosis.

Authors:  Xiao-Qing Wei; Helen Rogers; Michael A O Lewis; David W Williams
Journal:  Clin Dev Immunol       Date:  2010-10-24

Review 7.  Transplantation of haploidentically mismatched stem cells for the treatment of malignant diseases.

Authors:  Franco Aversa; Massimo F Martelli
Journal:  Springer Semin Immunopathol       Date:  2004-09-11

8.  Voriconazole for invasive aspergillosis in oncohematological patients: a single-center pediatric experience.

Authors:  Simone Cesaro; Liliana Strugo; Rita Alaggio; Giovanni Cecchetto; Luca Rigobello; Marta Pillon; Riccardo Cusinato; Luigi Zanesco
Journal:  Support Care Cancer       Date:  2003-09-13       Impact factor: 3.603

Review 9.  Aspergillosis and stem cell transplantation: An overview of experimental pathogenesis studies.

Authors:  Nadia Al-Bader; Donald C Sheppard
Journal:  Virulence       Date:  2016-09-29       Impact factor: 5.882

10.  Polymorphisms in Host Immunity-Modulating Genes and Risk of Invasive Aspergillosis: Results from the AspBIOmics Consortium.

Authors:  C B Lupiañez; L M Canet; A Carvalho; L Alcazar-Fuoli; J Springer; M Lackner; J Segura-Catena; A Comino; C Olmedo; R Ríos; A Fernández-Montoya; M Cuenca-Estrella; C Solano; M Á López-Nevot; C Cunha; A Oliveira-Coelho; T Villaescusa; L Fianchi; J M Aguado; L Pagano; E López-Fernández; L Potenza; M Luppi; C Lass-Flörl; J Loeffler; H Einsele; L Vazquez; M Jurado; J Sainz
Journal:  Infect Immun       Date:  2015-12-14       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.